Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.
Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.
Infinity had $104.6 million in cash and investments as of 30 June compared to a $104.9 million cash balance on...
Create an account to read this article
Already a subscriber?
The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.
The agency approved the subcutaneous formulation of the PD-1 inhibitor, months after approving a subcutaneous version of BMS’s Opdivo.
The drugmaker presented positive Phase II data for its BCMAxCD3-directed bispecific in high-risk smoldering myeloma patients.
Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.
The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.
Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.
India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.
